Avalyn Pharma Inc AVLN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile
-
Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors
-
Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
-
Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis
-
Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026
-
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Trading Information
- Previous Close Price
- $27.25
- Day Range
- $25.43–27.21
- 52-Week Range
- $22.24–40.17
- Bid/Ask
- $26.00 / $26.04
- Shares Outstanding
- 44.33M
- Market Cap
- $1.15B
- Volume/Avg
- 320,297 / 241,718
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.avalynpharma.com
Valuation
|
Metric
|
AVLN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.04 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AVLN
|
|---|---|
Quick Ratio | 32.76 |
Current Ratio | 33.12 |
Interest Coverage | — |
Quick Ratio
AVLN
Profitability
|
Metric
|
AVLN
|
|---|---|
Return on Assets (Normalized) | −41.29% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
AVLN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#Zv?G%w | LOCK|pJPr | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|xb$>%m$ | LOCK|gZsy# | $83B | |||
| Moderna Inc
MRNA
| LOCK|><!v>Zk | LOCK|Zz | $81B | |||
| argenx SE ADR
ARGX
| LOCK|G@<Cgn | LOCK|k< | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|DX%MTK$ | LOCK|j^ | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|GV?z$B | LOCK|C$Zs^ | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<T$Trn@% | LOCK|@!xK | $28B | |||
| Incyte Corp
INCY
| LOCK|f>gY!X& | LOCK|mV | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|%@#c#%S | LOCK|rT | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|JlBk%w< | LOCK|N? | $14B |
United States